ストックスクリーナーアプリを入手
2.29
4.58%
-0.11
アフターアワーズ：
2.29
前日終値:
$2.40
開ける：
$2.2001
24時間の取引高:
9,502
Relative Volume:
0.67
時価総額：
$45.79M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-14.87%
1か月 パフォーマンス:
+1.59%
6か月 パフォーマンス:
-66.42%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$2.20
$2.3414
1週間の範囲:
$2.20
$2.6608
52週間の値動き範囲:
$1.8107
$9.988
Lakeshore Biopharma Co Ltd Stock (LSB) Company Profile
LSB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LSB
Lakeshore Biopharma Co Ltd
|
2.29 | 45.79M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Lakeshore Biopharma Co Ltd (LSB) 最新ニュース
LakeShore Biopharma Announces Court Dismissal Of Former Chairman's Injunction Applications - MarketScreener
LakeShore Biopharma Adopts Amended Share Incentive Plan - TipRanks
YS Biopharma Shares Surge 18% Pre-Bell on Estimated Preliminary Revenue for Fiscal Year 2023 - Marketscreener.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Revenues Working Against LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Share Price Following 27% Dive - Simply Wall St
LakeShore Biopharma : Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full Year Guidance Form 6 K - Marketscreener.com
LakeShore Biopharma Posts First Profit Since 2013, Revenue Soars 36% in Strong H1 Earnings - StockTitan
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance - Finansavisen
LakeShore Biopharma provides update on ongoing investigation involving Yi Zhang - TipRanks
LakeShore Biopharma Pursues Criminal Investigation Against Ex-Chairman for Major Corporate Fraud - StockTitan
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - GlobeNewswire
LakeShore Biopharma Faces Challenges Amid Criminal Probe into Former Chairman - TipRanks
Omeros Corp (OMER) Stock Surges Amidst Biotech Sector Activity - GuruFocus.com
LakeShore Biopharma : Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan Form 6 K - Marketscreener.com
LakeShore Biopharma Granted Phase III Clinical Trial Approval to - GuruFocus.com
LakeShore Biopharma Initiates Biologics License Application - GlobeNewswire
LakeShore's Rapid Rabies Vaccine Breakthrough: FDA-Backed Solution Targets Pakistan Crisis | LSB Stock News - StockTitan
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66% - Simply Wall St
LakeShore Biopharma Co., Ltd Provides Financial Guidance for the Half Year of Fiscal Year of 2025 and Full Year of Fiscal Year 2025 Ending on March 31, 2025 - MarketScreener
LakeShore Biopharma regains Nasdaq compliance By Investing.com - Investing.com Canada
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - StreetInsider.com
LakeShore Biopharma regains Nasdaq compliance - Investing.com India
LakeShore Biopharma Advances with Rabies Vaccine Trial - Yahoo Finance
LakeShore Biopharma to test simplified rabies vaccine regimen By Investing.com - Investing.com Australia
LakeShore Biopharma's YSJA Rabies Vaccine Heads To Phase III Trial - Contract Pharma
LakeShore Biopharma to test simplified rabies vaccine regimen - Investing.com
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine - StockTitan
YS Biopharma (YSB) Stock Price, News & Analysis - MarketBeat
LakeShore Biopharma projects steady growth for FY2025 By Investing.com - Investing.com Australia
LakeShore Biopharma projects steady growth for FY2025 - Investing.com
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance - The Manila Times
LakeShore Biopharma Updates Corporate Framework - TipRanks
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation - Kilgore News Herald
LakeShore Biopharma Calls for Shareholder Vote on Stock Compliance - TipRanks
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 - StockTitan
LakeShore changes CEO with new executive appointments - The Pharma Letter
LakeShore Biopharma Announces Leadership Transitions - PR Newswire
YS Biopharma COVID-19 Vaccine Candidate Against Omicron Variant Meets Primary, Secondary Goals - Marketscreener.com
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - The Manila Times
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - simplywall.st
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - PR Newswire
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough - Simply Wall St
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): When Will It Breakeven? - Yahoo Finance
LSB Stock Price and Chart — NASDAQ:LSB - TradingView
YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS - Marketscreener.com
YS Biopharma Co., Ltd. Announces Chief Executive Officer Changes - Marketscreener.com
YS Biopharma Announces Name Change to LakeShore Biopharma - PR Newswire
YS Biopharma Announces Results of Extraordinary General Meeting - PR Newswire
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer - PR Newswire
YS Biopharma to host EGM and appoints new Interim CEO By Investing.com - Investing.com UK
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PR Newswire
Lakeshore Biopharma Co Ltd (LSB) 財務データ
Lakeshore Biopharma Co Ltd (LSB) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.00%
大文字化:
|
ボリューム (24 時間):